Ipsen is acquiring Kartos Therapeutics to get navtemadlin, which has reached Phase 3 testing in the blood cancer myelofibrosis. The Kartos oral small molecule takes a novel approach to restoring the function of p53, a tumor-suppressing protein.
The post Ipsen’s $450M Deal Brings Drug That Could Make a Standard Blood Cancer Therapy Better appeared first on MedCity News.
